What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Gene
- Cancer
Cell biology, Immunology, Progenitor cell, Kidney and Internal medicine are her primary areas of study.
Her Cell biology research integrates issues from Endothelial stem cell, IL-2 receptor, Cellular differentiation, CD40 and Podocyte.
Her Immunology study often links to related topics such as Histamine.
Stem cell covers she research in Progenitor cell.
Her Kidney research is multidisciplinary, incorporating elements of Extracellular, Renal stem cell and Pathology.
Her work investigates the relationship between Internal medicine and topics such as Endocrinology that intersect with problems in Kupffer cell.
Her most cited work include:
- Phenotypic and functional features of human Th17 cells. (1546 citations)
- Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells (1046 citations)
- Isolation and Characterization of Multipotent Progenitor Cells from the Bowman’s Capsule of Adult Human Kidneys (577 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Internal medicine, Immunology, Kidney, Cell biology and Pathology.
Her research in Internal medicine intersects with topics in Gastroenterology, Endocrinology and Nephropathy.
Her Endocrinology research focuses on Receptor and how it connects with Endothelial stem cell.
Her work in Immunology addresses subjects such as Kidney transplantation, which are connected to disciplines such as Urinary system.
She has included themes like Renal stem cell, Stem cell and Kidney disease in her Kidney study.
Her Cell biology study combines topics in areas such as IL-2 receptor and Induced pluripotent stem cell.
She most often published in these fields:
- Internal medicine (31.88%)
- Immunology (26.45%)
- Kidney (27.90%)
What were the highlights of her more recent work (between 2018-2021)?
- Kidney disease (15.94%)
- Internal medicine (31.88%)
- Acute kidney injury (11.96%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Kidney disease, Internal medicine, Acute kidney injury, Cell biology and Kidney.
The various areas that Paola Romagnani examines in her Kidney disease study include Uric acid, Immunology, Intensive care medicine, Disease and Fibrosis.
Her Immunology research includes elements of Regulator and Gene.
Her study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Endocrinology, Nephropathy and Rituximab.
Progenitor cell and Stem cell are the primary areas of interest in her Cell biology study.
Paola Romagnani combines subjects such as Cancer and Extracellular matrix, Decellularization with her study of Kidney.
Between 2018 and 2021, her most popular works were:
- Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells. (26 citations)
- Mitochondria Permeability Transition versus Necroptosis in Oxalate-Induced AKI. (23 citations)
- Molecular Mechanisms of the Acute Kidney Injury to Chronic Kidney Disease Transition: An Updated View. (22 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
Paola Romagnani mainly focuses on Fibrosis, Internal medicine, Acute kidney injury, Immune system and Kidney disease.
Her Fibrosis research is multidisciplinary, relying on both Eosinophilia and Infiltration.
Her Internal medicine study incorporates themes from Gastroenterology and Nephropathy.
The concepts of her Acute kidney injury study are interwoven with issues in Cell, Acute tubular necrosis, Immunology, Pathophysiology and Endothelium.
Her work carried out in the field of Immune system brings together such families of science as Fibrocyte, Biopsy and Pathology.
Her Hyperuricemia research is classified as research in Endocrinology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
